Tradiční hepatoprotektiva v terapii MASLD. Jaká je klinická evidence účinku?
| Title in English | Traditional hepatoprotective agents in MASLD therapy. What is the clinical evidence of effect? |
|---|---|
| Authors | |
| Year of publication | 2025 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| Keywords | MASLD, NAFLD, silymarin, essential phospholipids |
| Description | The article discusses non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, and its renaming to metabolic dysfunction-associated liver steatosis (MASLD) by professional societies in 2022. It briefly outlines pharmacotherapy options but primarily focuses on evaluating the efficacy of traditional hepatoprotective agents registered in the Czech Republic – silymarin and essential phospholipids – for MASLD treatment. A systematic search of the Web of Science database identified six studies on essential phospholipids and nine on silymarin; the search was made without restrictions on patient numbers, follow-up duration, or publication period. While both agents improve some laboratory parameters, the evidence supporting their routine clinical use remains insufficient. This is reflected in current clinical guidelines, which do not recommend traditional hepatoprotective agents for MASLD treatment. |
| Related projects: |